HEOR

Health Economics & Outcomes Research Fellowships

2026-2028

U NOVARTIS | Reimagining Medicine

Novartis is a world leader in the research and development of products to protect and improve health and well-being.

Novartis was created in 1996 from the merger of the Swiss companies Ciba-Geigy and Sandoz. Novartis Pharmaceuticals is dedicated to discovering, developing, manufacturing, and marketing prescription drugs to prevent and cure diseases, to ease suffering and to enhance quality of life. Novartis' portfolio of products is directed toward cardiovascular, multiple sclerosis, immunology, hepatology, and dermatology, organ transplantation, ophthalmology, oncology and hematology, and other therapeutic areas.

Novartis, derived from the Latin novae artes, meaning "new skills," is committed to using new skills to improve health and well-being through innovative products and services. Recognizing an increasing need for outcomes information, resources and expertise, the Health Economics & Outcomes Research (HEOR) departments at Novartis strive to be best-in-class in the generation of outcomes evidence that demonstrates value and optimizes patient access to Novartis products. This is accomplished through execution of burden and cost-of-illness studies, economic evaluations alongside clinical trials, comparative effectiveness research, cost-effectiveness analyses, prospective observational studies such as effectiveness registries, retrospective claims database analyses and patient-reported outcomes research.

Purpose

The Health Economics & Outcomes Research (HEOR) Fellowship Program provides training and hands-on experience in a broad range of health economics, outcomes research and comparative effectiveness research (CER) opportunities. This 2-year program is structured to allow the Fellows to gain proficiency in the field of health economics, outcomes research and CER as conducted in academic, managed care, hospital, health policy and/or pharmaceutical industry settings.

Overview

Novartis Pharmaceuticals Corporation is pleased to offer three 2-year Health Economics & Outcomes Research (HEOR) Fellowship positions for the 2026-2028 cycle.

The objective of the first year is to educate the fellow on general principles and methods applied in health economics and outcomes research. Concurrently, the fellow will participate in ongoing outcomes research projects at the first year fellowship site. All Fellows will spend the second year of the Fellowship at the US-based headquarters of Novartis Pharmaceuticals Corporation located in East Hanover, New Jersey.

While at Novartis, "field-based" training will be undertaken as part of the Fellowship training. Fellows will participate in health economics and outcomes research projects and gain experience in how a pharmaceutical manufacturer uses clinical, economic, and humanistic data to support the development and commercialization of its products, with opportunities in dermatology, cardiovascular franchises and renal franchises.

The fellowship positions differ by first-year site requirements and type of experience offered. Each position is described in this brochure. Compensation includes a competitive stipend, basic medical insurance, holiday and vacation time, plus other benefits associated with each specific academic/managed care institution.

First-Year Fellowship Sites for 2-Year Programs (3 Positions):

- Baylor Scott & White Health, Temple, TX/
  The University of Texas at Austin, Austin, TX
  (1 position)
- Jefferson College of Population Health,
  Thomas Jefferson University, Philadelphia, PA
  (1 position)
- University of Pittsburgh School of Pharmacy/
  UPMC Health Plan, Pittsburgh, PA
  (1 position)

Fellowship Alumni: Where Are They Now?

- 18% Biopharma/Start-up
- 55% Pharma
- 9% Hospital & Healthcare
- 6% PBM/Payer
- 6% Consulting
- 5% Academia
- 1% Retail

Contact

Please contact current Fellows for any site-specific questions (contact information provided on subsequent pages).

For inquiries regarding general application or interview process, please contact:

> Monika Salkar, PhD, BPharm
> Associate Director, HE&OR and
> HE&OR Fellowship Director
> East Hanover, NJ
> usheor.fellowship@novartis.com

Novartis Pharmaceuticals Corporation/ Baylor Scott & White Health/ The University of Texas at Austin

Fellowship Sites & Preceptors

Baylor Scott & White Health

Paul Godley, PharmD, FASHP, BCPS, System Director, Specialty Pharmacy, Temple, TX

The University of Texas at Austin College of Pharmacy

Chanhyun Park, PhD, MPharm, MEd, RPh, Assistant Professor of Health Outcomes, Austin, TX

Novartis Pharmaceuticals Corporation

Monika Salkar, PhD, BPharm, Associate Director, HE&OR and HE&OR Fellowship Director, East Hanover, NJ

Baylor Scott & White Health/The University of Texas

Baylor Scott & White is an integrated healthcare system in central Texas. The Scott & White Health Plan is a health maintenance organization that has over 400,000 members and is affiliated with the Baylor Scott & White Quality Alliance, the system's accountable care organization, which represents over 6,000 physicians. Baylor Scott & White is affiliated with the College of Medicine, Texas A&M University Health Science Center, and the College of Pharmacy, The University of Texas at Austin.

The Department of Pharmacy at Baylor Scott & White provides progressive and innovative pharmaceutical services in a variety of environments for all components of the institution. Included are clinical and distributive services for the hospital, clinic and health plan, as well as sponsorship of pharmaceutical care programs and ambulatory care clinics focusing on lipid, diabetes and anticoagulation management. Fellows will gain significant understanding of the key issues involved in pharmacy services provided by prescription benefits management and managed care organizations. The integrated character of the institution and the Department of Pharmacy provides significant opportunities for pharmacy practice, research and education.

The Health Outcomes and Pharmacy Practice Division, College of Pharmacy, The University of Texas at Austin, is one of the preeminent educational institutions for pharmacy education in the nation. The college is located in downtown Austin, and the Fellow is offered the option of pursuing the Master of Science degree in Pharmaceutical Sciences at the University of Texas, Austin. The degree would be granted at the end of the Fellowship provided that the required coursework and thesis have been completed. The recommended course of study is designed to assist the Fellow in coordinating required and recommended coursework along with the Fellowship requirements.

However, the coursework is tailored based on individual interests, background and career goals. Additionally, the College is home to TxCORE (Texas Center for Health Outcomes Research and Education), which is a leader in addressing population and individual health through innovative, high-quality research, and education, and serves the community by responding to critical health care issues that impact patients' daily lives. TxCORE combines the strengths of its nationally recognized clinical, pharmacy, social and behavioral, economics, and policy researchers to collect, analyze, and interpret data, and disseminate research findings throughout the many sectors of the health care industry, government, and private sector organizations.

The unique nature of the Baylor Scott & White integrated healthcare system, combined with the pharmacoeconomic expertise at the College of Pharmacy, offers significant opportunity for individuals interested in the Novartis Fellowship experience.

Eligibilty

Eligible candidates must have a doctorate in pharmacy or the combination of an undergraduate degree in pharmacy plus an advanced degree in health services research, public health, health policy, pharmacy, economics, medicine or other related area. Experience in, or at a minimum, exposure to some aspect of outcomes research, health economics or another related field of research is preferred.

Information

For questions or additional information, please contact:

Beverly Fuerte, PharmD
Health Economics & Outcomes Research Fellow
Email: beverly.fuerte@bswhealth.org

All questions regarding potential visa sponsorship should be directed to the collaborating institution.

First-Year Fellow:
Beverly Fuerte, PharmD

Beverly Fuerte is a first-year Fellow in Health Economics and Outcomes Research (HEOR) with Novartis, Baylor Scott & White, and The University of Texas at Austin.

Beverly received her Doctor of Pharmacy and Certificate in Healthcare Decisions Analysis from the University of Southern California Mann School of Pharmacy. In her coursework, Beverly not only learned about the fundamentals of pharmacy practice, she also gained insight on biopharmaceutical pricing strategies and competitive healthcare intelligence. Beverly has had extensive clinical and administrative experience across a range of health care settings including Kaiser Permanente where she worked in the community setting, and the Los Angeles Department of Health Services where she was involved in projects that oversee cost-avoidance of pharmacist-led protocols for cancer infusions as well as contribute to Pharmacy & Therapeutics (P&T) formulary decision making.

Beverly published research in the journal, Pharmacogenetics and Genomics, in which she led the investigation of cost-savings of TPMT/NUDT15 pharmacogenomic testing for 6-mercaptopurine in pediatric acute lymphoblastic leukemia patients. She also participated in the annual Academy of Managed Care Pharmacy P&T Competition where she directed pharmacoeconomic and cost-effectiveness research for monograph development and presentation. These experiences have culminated her initial interest in HEOR, and she hopes to deepen her understanding and enhance applications of HEOR principles in her work through the Novartis fellowship.

During her first year, Beverly will collaborate with pharmaceutical companies to conduct studies assessing clinical outcomes, prescribing patterns, and health spending at Baylor Scott & White while pursuing a Master's degree in Pharmaceutical Science from the Division of Health Outcomes and Pharmacy Practice at the University of Texas at Austin. She will also support clinical teams such as the Antimicrobial Stewardship and P&T Committee.

Second-Year Fellow:
Raquel (Skyla) Erb, PharmD

Raquel (Skyla) Erb is a second-year Health Economics and Outcomes Research (HEOR) Fellow with Baylor Scott & White Health and Novartis Pharmaceutical Corporation.

Skyla earned her Doctor of Pharmacy degree from the University of Texas at Austin and is currently pursuing a Master's in Pharmaceutical Science. During pharmacy school, she gained experience in managed care settings, where she conducted research using health claims data across Medicare and Commercial populations. Her interest in HEOR was further solidified through an AMCP Foundation Specialty Care internship with Sanofi and Blue Cross NC, where she explored patient preferences for hemophilia therapies and completed a rotation with the FDA's Center for Devices and Radiological Health.

In the first year of her fellowship at Baylor Scott & White Health, Skyla supported proposals for industry-sponsored research focused on medical utilization in COPD and CLL populations. She also led outcomes research projects on reduced readmissions among rifaximin-treated patients with hepatic encephalopathy and statistical analysis on appropriate statin prescribing for patients living with HIV. Additionally, Skyla is participating in an NIH-funded AI training program through the AIM-AHEAD and BRIDGE2AI Consortium, where she is learning to apply cutting-edge artificial intelligence methods to healthcare research.

In her second year at Novartis, Skyla supports HEOR activities within the Cardiovascular, Metabolism, and Nephrology (CVM/Neph) Team. She collaborates cross-functionally with internal and external stakeholders, contributing to projects from conceptualization through data dissemination. Her current work includes retrospective claims analyses and strategic planning for product launches. Skyla aspires to leverage her fellowship experience to pursue a future leadership role as an HEOR manager.

Novartis Pharmaceuticals Corporation/ Thomas Jefferson University, Jefferson College of Population Health

Fellowship Sites & Preceptors

Thomas Jefferson University

Vittorio Maio, PharmD, MS, MSPH, Professor and Director, Health Economics and Outcomes Research Fellowship, Jefferson College of Population Health, Thomas Jefferson University, Philadelphia, PA

Novartis Pharmaceuticals Corporation

Monika Salkar, PhD, BPharm, Associate Director, HE&OR and HE&OR Fellowship Director, East Hanover, NJ

College of Population Health, Thomas Jefferson University

Established in 2008, the Jefferson College of Population Health (JCPH) is one of six colleges that comprise Thomas Jefferson University, founded in 1824 as Jefferson Medical College. JCPH builds upon the 18-year history of Jefferson's Department of Health Policy and specializes in all key areas of population health–public health, health policy, healthcare quality and safety,and applied health economics and outcomes research (AHEOR). The College has one of the oldest and most established outcomes research Fellowship programs in the country. To date, over 80 individuals have completed JCPH Fellowships and have successfully pursued careers in all sectors of the healthcare industry, including government, pharmacy, insurers and consulting.

During the first year, the Fellow will work in JCPH at the University's Philadelphia Center City campus and be assigned to manage specific outcomes research projects. As a member of the JCPH research team, s/he has the opportunity to attend and present at research meetings, journal clubs, Population Health Forums and sponsored educational programs. S/he may also contribute to any one of several graduate level classes taught by JCPH faculty in the College's public health, AHEOR, health policy, healthcare quality and safety, population health intelligence and population health graduate programs. The Fellow will develop writing skills through completion of a writing seminar, peer review of continuing education articles and authorship of manuscripts for publications edited by American Journal of Medical Quality, Population Health Management, and Population Health Matters.

Networking is also an important activity during the first year. The Fellow will interact with decision makers from both within the University and from a broad variety of organizations, including pharmaceutical and device manufacturers, health plans and other health-related employers. The Fellow will regularly meet with JCPH faculty and staff to discuss research projects and academic experiences, and s/he will be assigned a faculty mentor to coach him/her during the first year. Completion of master's level coursework through JCPH is a formal component of this Fellowship and serves to develop the knowledge and skills required for health economics and outcomes research. The Fellow has the option to complete a fully supported graduate Certificate or Master of Science degree program in public health, population health, population health intelligence, health policy or applied health economics and outcomes research.

The second year of training will take place at Novartis, located in East Hanover, New Jersey. During this time, under the guidance of a Novartis preceptor, the Fellow will work directly with the HEOR department at Novartis for a period of one year in order to further their educational objectives by gaining applied experience in health economics and outcomes research. In addition to project work, the Fellow will participate in meetings to share his or her work and further develop networkingand presentation skills.

Eligibilty

Eligible candidates should have an advanced degree in health services research, public health, economics, epidemiology, pharmacy, pharmacy administration or a related discipline. A background in pharmacy or medicine and experience in outcomes research, health economics or another related field of research is preferred. Candidates must have excellent written and verbal communication skills.

Information

For questions or additional information, please contact:

Vietbao Phan, PharmD
Health Economics & Outcomes Research Fellow
Email: vietbao.phan@jefferson.edu

All questions regarding potential visa sponsorship should be directed to the collaborating institution.

First-Year Fellow:
Vietbao Phan, PharmD

Vietbao is a first-year Health Economics & Outcomes Research (HEOR) Fellow with the Jefferson College of Population Health (JCPH) and Novartis Pharmaceuticals Corporation.

Vietbao earned his Doctor of Pharmacy from Thomas Jefferson University in Philadelphia. His interest in HEOR began in his first year of pharmacy school through a Pharmacy and Therapeutics (P&T) competition, where he explored formulary decision-making and value-based care. This early exposure laid the foundation for a growing passion for evidence generation and its role in improving healthcare decisions. He later contributed to a scoping review evaluating psychosocial interventions for pregnant women with opioid use disorder, assessing how these interventions impact maternal health outcomes. He also participated in a systematic review examining patient preferences for medication-assisted treatment, emphasizing the role of patient-centered care and shared decision-making in treatment engagement and retention. His interest in HEOR deepened through coursework in Pharmacoeconomics and Health Outcomes, where he explored the relationship between treatment cost and clinical outcomes across therapeutic areas.

During his first year at JCPH, Vietbao will be engaged in projects involving manuscript writing, cost-effectiveness research, modeling, qualitative and quantitative research. He is also pursuing a master's degree in applied health economics and Outcomes Research. Vietbao is committed to generating real-world evidence and applying economic frameworks to inform access, reimbursement, and policy decisions. His goal is to produce actionable insights that promote value-based care and support sustainable, patient-centered healthcare.

Second-Year Fellow:
Mumbi Kimani, PhD, MA

E. Mumbi Kimani is a second-year Health Economics & Outcomes Research (HEOR) Fellow with the Jefferson College of Population Health (JCPH) and Novartis Pharmaceuticals Corporation. She holds a PhD in Economics from the University of Cape Town, South Africa. Prior to joining the fellowship, she served as a faculty member at the Pennsylvania State University. During her tenure at Penn State, in addition to teaching econometrics and global health policy courses, she engaged in research was published in leading journals such as JAMA Network Open and PLOS ONE.

During her first year at JCPH, Mumbi contributed to several projects including a retrospective study on utilization, clinical outcomes, and costs of partial nephrectomy surgical procedures; systematic literature reviews to evaluate the efficacy, quality of life, and safety of combining radioligand therapy (RLT) with systemic treatments in neuroendocrine tumors (NETs); and a cost-effectiveness analysis of radical nephrectomy techniques in treatment of renal cell carcinoma (RCC). Concurrently, she is pursuing an MS in Applied Health Economics and Outcomes Research at JCPH to deepen her technical expertise.

In her second year at Novartis, Mumbi plays a key role in advancing the US HEOR Oncology team's research initiatives. She is involved in designing and overseeing studies while fostering collaborations across internal and external stakeholders, driving projects from early concept development to final dissemination. Her current work spans from a patient-reported outcomes survey, a mixed-method claims analysis, and program evaluation –all aimed at generating actionable insights. Combining rigorous economic analysis with a passion for healthcare innovation, Mumbi is committed to transforming enhancing healthcare systems— enhancing their efficiency, equity, and effectiveness through data-driven research and evidence-based solutions.

Novartis Pharmaceuticals Corporation/ University of Pittsburgh School of Pharmacy/ UPMC Health Plan (1 position)

Fellowship Sites & Preceptors

University of Pittsburgh School of Pharmacy

Kangho Suh, PharmD, PhD, Assistant Professor, Department of Pharmacy & Therapeutics, Pittsburgh, PA

UPMC Health Plan

Chester "Bernie" Good, MD, MPH, Senior Medical Director, Center for Value-Based Pharmacy Initiatives, Pittsburgh, PA

Samuel Peasah, PhD, RPh, MBA, Director, Center for Value-Based Pharmacy Initiatives and Adjunct Associate Professor, University of Pittsburgh School of Pharmacy, Pittsburgh, PA

Novartis Pharmaceuticals Corporation

Monika Salkar, PhD, BPharm, Associate Director, HE&OR and HE&OR Fellowship Director, East Hanover, NJ

The University of Pittsburgh School of Pharmacy/UPMC Health Plan

UPMC Health Plan, headquartered in Pittsburgh, Pennsylvania, is among the nation's fastest-growing health plans. It is owned by the University of Pittsburgh Medical Center (UPMC), a world-renowned integrated health care delivery and financing system. The UPMC Health Plan is committed to providing its members better health, through an evidence-based insurance design and generous pharmacy benefit. The Center for High-Value Healthcare (CHVHC) is a nonprofit research organization housed within UPMC Health Plan that translates, through research and collaboration, the work of the UPMC Insurance services into evidence-based practice and policy change. The Center for Value-based Pharmacy Initiatives is a center within CHVHC that focuses on value/outcomes-based contracts and pharmacy-related outcomes research in collaboration with the pharmacy department of the Health Plan and other external partners.

University of Pittsburgh is one of the oldest institutions of higher education in the United States. It was ranked as the No. 1 public university in the Northeastern United States in 2020 and is ranked in the top 20 among the nation's top public colleges and universities. At the School of Pharmacy, the Fellow will have the opportunity to earn an online Master of Science in PharmacoAnalytics – Pharmaceutical Outcomes Research. This program provides students with tools and skills necessary to analyze large, healthcare datasets and apply data analytic and pharmacoepidemiology concepts to enhance pharmaceutical use and outcomes. A key feature of this program is competency-based learning, which requires students to demonstrate application of didactic learning through hands-on analysis of real-world data and evidence. Students will develop core competencies related to study design, data collection, data management, data organization, data analysis, and data visualization/communication.

The intersection of managed care, academia, and opportunities to lead outcomes research projects will enable the Pitt Pharmacy and UPMC Health Plan 1st year site to equip the fellow with the necessary skills and abilities to succeed in the 2nd year at Novartis and beyond.

Eligibilty

Eligible candidates must have a doctorate in pharmacy. Experience in, or at a minimum, exposure to some aspect of outcomes research, health economics or another related field of research is preferred.

Information

For questions or additional information, please contact:

Steven Do, PharmD
Health Economics & Outcomes Research Fellow
Email: scd99@pitt.edu

All questions regarding potential visa sponsorship should be directed to the collaborating institution.

**First-Year Fellow:
Steven Do, PharmD**

Steven is a first-year Health Economics & Outcomes Research (HEOR) fellow with Novartis Pharmaceutical Corporation, the University of Pittsburgh, and University of Pittsburgh Medical Center (UPMC) Health Plan.

Steven received his Doctor of Pharmacy and Operations and Technology Management Named Option from the University of Wisconsin - Madison School of Pharmacy (UW Madison). His interest in HEOR comes from his background in health outcomes research and quality improvement work. During his time at UW Madison, Steven participated in several projects such as leveraging national administrative data to measure the impact of a pharmacist led Chronic Obstructive Pulmonary Disease (COPD) transitions of care program on patient outcomes, care quality, and access to care. His work has been presented at the Annual Conference on the Science of Dissemination & Implementation in Health and American Thoracic Society International Conference.

During his first year, Steven will be involved in healthcare utilization analysis, development of value-based contract concepts, and economic modeling in various research projects at the University of Pittsburgh and UPMC Health Plan's Center for High-Value Health Care (CHVHC). Alongside these projects, he is pursuing a master's degree in PharmacoAnalytics - Pharmaceutical Outcomes Research. Steven looks forward to cultivating his HEOR knowledge through a combination of managed care, academic, and industry experiences during the fellowship.

**Second-Year Fellow:
Cindy Chan, PharmD, MHI**

Cindy Chan is a second-year Health Economics & Outcomes Research (HEOR) Fellow at Novartis in collaboration with University of Pittsburgh and UPMC Health Plan.

Cindy earned her Doctor of Pharmacy and Master of Health Informatics at the University of Minnesota. As a pharmacy student, her internship at Blue Cross and Blue Shield of Minnesota and achievement of winning National Third Place in the 2023 AMCP P&T Competition strengthened her skills and interest in claims data analyses and economic modeling. She also gained valuable insights into value-based contracting, market research, and new business development through pharmacy rotations at Eli Lilly and Cencora.

During the first year of her fellowship, Cindy led projects on administrative claims analysis, economic modeling, and systematic review across therapeutic areas including atopic dermatitis, schizophrenia, diabetes, and oncology. She also gained unique exposure to value-based contract development and formulary management strategy at UPMC Health Plan. At ISPOR 2025, she presented two research posters and received the Best Student Podium Research Presentation Award with her podium presentation on the cost-effectiveness of second-generation antipsychotics long-acting injectables in schizophrenia.

As a second-year fellow at Novartis, Cindy currently supports the US HEOR Immunology team on a variety of HEOR tactics including retrospective database analysis, systematic review, budget impact modeling, and value dossier. She also collaborates with cross-functional colleagues in Medical Affairs and Market Access teams on strategic planning for pipeline product launches. She is currently completing her thesis for a Master of Science in PharmacoAnalytics at the University of Pittsburgh.

Previous Fellows

Neetu Agashivala, MS
Executive Director, Oncology & Immunology HEOR, International,
Novartis

Adaeze Amaefule, PharmD, MS
Associate Director HEOR,
Disc Medicine

Lauren Bartolome, PharmD, MS
Director, HEOR I&I,
Pfizer

Kelly Fee Bell, PharmD, MSPhr
Value Evidence Lead,
GlaxoSmithKline

William Boyko, PharmD
Pharmacist Consultant,
P&C Pharma

Cat Bui, PharmD, PhD
Senior Director, Oncology HEOR Strategy,
AbbVie

Scott Bull, PharmD
Director, Clinical Project Scientist,
Johnson & Johnson Innovative Medicine

Beilei Cai, PhD, MA
Senior Director, HEOR - Cardiovascular,
Novartis

Aaron Carabajal-Johnson, PharmD, MS
Senior Manager, Global HEOR & RWE,
Baxter International Inc.

Swetha Challagulla , MS
Director, Global HEOR Hematology,
BeiGene

Jane Chang, MPH
Senior Director, Value & Evidence Lead, GU Cancer,
Pfizer

Michelle Choi, PharmD
Senior Medical Science Liaison-Immunology,
Sanofi

Paul C. Cockrum, PharmD, DPh
Lead, US Health Outcomes Field Team,
Vera Therapeutics, Inc.

Arijita Deb, PhD
Director, Value Evidence and Outcomes,
GlaxoSmithKline

Laurence Djatche, PharmD, MS
Global Health Economics & Value Assessment Business Partner,
Sanofi

QuynhChau Doan, PhD, RPh, MS
Director, Health Systems & Outcomes,
Intercept Pharmaceuticals

Joseph Doyle, RPh, MBA

Batul Electricwala, PhD
Director, HEOR,
Novartis

John Fastenau, PhD, MPH, RPh
Executive Director, Health Economics Outcomes Research,
Insmed Incorporated

Feride Frech, PhD, MPH
Senior Director, HEOR & RWE,
Eisai, Inc.

Rahul Garg, PhD
Director of Evaluation and Outcomes Assessment,
Alabama College of Osteopathic Medicine

Joseph Goble, PharmD, MS
Director, National Accounts, Value & Evidence Scientific
Engagement,
Johnson & Johnson Innovative Medicine

Boris Gorsh, PharmD, MS
Sr. Director, Global Oncology HEOR and RWE,
Daiichi Sankyo, Inc.

Geneen Graber Maxwell, PharmD
President and CEO,
Dr. G's Pharmacy

Bill Grant, PhD
Associate Professor of Economics, College of Business,
James Madison University

Amy Grogg, PharmD
Strategic Advisor,
Vesey Street Capital Partners

Kristy Hanson, PharmD, MS
Scientific Consultant, Value Demonstration,
United BioSource Corporation:
An Express Scripts Company

Peter Hur, PharmD, MBA
Director, Worldwide HEOR Oncology,
Pfizer

Archie Jackson, PharmD
Chief Operating Officer,
A&S Healthcare Consulting and Analytics, Inc.

Tom Karagiannis, PharmD, MS
Head, Immunology Market Access & HEOR (Canada),
AbbVie

Jennifer Kim, PharmD
Director, Global Pricing and Market Access,
AstraZeneca

John Kim, PharmD
Executive Director, Head of Global Market Access,
Seagen

Nina Kim, PharmD, MS
Associate Director, Real World Value & Evidence, Oncology,
Johnson & Johnson Innovative Medicine

Yoona Kim, PharmD, PhD
Co-founder and CEO,
Arine

John Ko, PharmD, MS
Senior Director, Med Affairs, Value & Evidence Strategy,
Beam Therapeutics

Amy Law, PharmD, MS
Director, Value & Evidence (RSV Vaccines),
Pfizer

Junji Lin, PhD
Associate Director,
Jazz Pharmaceuticals

Jackie Lu, PharmD, MS
VP of Corporate and Business Development,
CDH Pharma

Mario Luong, PharmD, MPH
Director of Operations,
Optum

Shilpa Mehta, PharmD
AVP, Global Oncology Portfolio Lead - Merck | Daiichi Sankyo
Collaboration,
Merck & Co, Inc

Patrick Mends, PharmD

Jeannie Menz, PharmD
Director, Content Development and Training,
Sandoz

Laetitia N'Dri, PharmD, MS
Associate Director, US Health Economics & Outcomes Research,
Bristol Myers Squibb

Gilbert C. Ngan, PharmD
Pharmacist: Part D Benefits Analyst,
CMS

Cindy Nguyen, PhD, RPh, MS
Senior Associate Director, HEOR Value Evidence and
Outcomes Liaison,
Boehringer Ingelheim

Jennifer Nguyen, PharmD, MS
Associate Director, US HEOR Oncology/Radioligand Therapies,
Novartis

Lina Nol-Heiring, BS, MBA
Senior Therapeutics Sales Specialist,
LEO Pharma

Engels Obi, PhD
Director, Global Outcomes Research | Value & Implementation Lead
| Metabolism,
Merck

Grace Oh (Chun), PharmD
Associate Director, US Medical Affairs Oncology,
Bristol Myers Squibb

Jacqueline B. Palmer, PharmD, MBA
Director, Professional Promotions Marketing,
Novartis

Jina Park, PharmD
Chief Strategy Officer,
AIRS Medical

Natalie (Siyeon) Park, PharmD, MS
Co-founder and CEO,
Pharmesol

Shivangi Patel, PharmD, MS
Senior Manager, Global Health Economics and Outcomes Research,
Amgen

Hoa T. Pham, PharmD
Senior Director, Field HEOR,
Beigene

Ngan Pham, PharmD, MS
VP Segment Strategy, Partnerships,
Komodo Health

Craig Plauschinat, PharmD, MPH
Director, HEOR & RWE,
Eisai, Inc.

Shibani Pokras, MPH
Senior Director, Global RWE & Health Outcomes Lead, Vaccines,
GlaxoSmithKline

Karim Prasla, PharmD, MS
Vice President, Clinical Outcomes, Analytics, and Reporting,
Prime Therapeutics

Karina Raimundo, BS Pharmacy, MS
Senior Director Evidence Business Partner,
Genentech, Inc.

David Ray, PharmD, MBA, MPH
Head of Integrated Evidence Generation (HEOR & ISTs),
Karyopharm Therapeutics, Inc.

Seon Young Ryu, PharmD
Mom/Independent Consulting,
Previously at Genentech

Rahul Sasané, PhD, MS, BPharm
Head - Global Value and Access,
Cerevel Therapeutics, LLC

Veronica Sendersky, PharmD
Managing Director,
Excellentia Pharma Consulting

Amishi Shah, PharmD
Oncology Medical Reviewer,
Merck

Hemal Shah, PharmD
President/Founder,
Value Matters, LLC

Karisha Shelley, PharmD, MS
Director, Health Economics & Outcomes Research (HEOR) - Global
Oncology,
Bristol Myers Squibb

Slaven Sikirica, MS
Senior Director, Head of HEOR,
Lexicon Pharmaceuticals, Inc.

Anh Singhania, PharmD
Senior Director, Health Systems & Outcomes, Medical Affairs
Intercept Pharmaceuticals

Bhavini Patel Srivastava, MS, BS Pharmacy
Director, HEOR,
AbbVie

Liz Stanley Smart, MPH
Global HEOR Lead, Eye Health,
Boehringer Ingelheim

Kangho Suh, PharmD, PhD, MS
Assistant Professor,
University of Pittsburgh

Dusica Tasic, MS, BS Pharmacy
Health Economics Manager,
GE Healthcare

Devi Thaker, PharmD, MS
Director, PharmacoAnalytics,
Express Scripts

Karishma Thakkar, PharmD, MS
Senior Manager, HEOR Product Lead
Novartis

Ryan Thaliffdeen, PharmD, MS
Associate Director, Global Value & Access, HEOR Center of
Excellence - Modelling,
Gilead Sciences

Melody Tran, PharmD, MS
Medical Outcomes Liaison,
Abbott Laboratories

Yuen Tsang, PharmD, MPH
Associate Director, Real World Value & Evidence,
Janssen Pharmaceuticals

Charlene Tugwete, PharmD, MS
HEOR Manager,
AbbVie

Stuart Turner, MPH
TA Head, General Medicines - Global RWE & Outcomes Research,
GlaxoSmithKline

Stefan Varga, PharmD, MS
Director, Worldwide Medical Affairs,
Bristol Myers Squibb

Ashok Vegesna, PharmD, MS
Director, Market Access Strategy - Breast & Women's Cancer,
Novartis

Joel Wallace, PharmD, MBA, MPH
Head, Gloval Value & Access,
Exelixis

Alexandra Wallem, PhD, RPh, MS
Advisor: Research Scientist and Analyst,
Eli Lilly

Xiaoxia (Summer) Wang, PharmD, PhD, MS
Associate Director, RWD Analytics and Innovation - Oncology,
Merck

Pin Xiang, PharmD, MS, MBA
Director of HEOR Value Demonstration - CNS,
Boehringer Ingelheim

Esther Yi, PharmD, MS
Director, Value & Evidence, Inflammation and Immunology Pipeline/
Business Development,
Pfizer

Krista Yokoyama, PharmD
Senior Manager, Pharmacy Analytics,
Blue Shield of California

Jing Yuan, PhD
Associate Professor,
Fudan University

HEOR Fellowship Application Form

Please type or print

Date: _____

Name: _____

Last   First   MI

Address: _____

Street   City   State   Zip Code

Phone: _____   _____

Primary   Secondary

Email: _____

Undergraduate and Graduate Degree(s) (date received or expected):

_____   _____

_____   _____

2-Year Programs (Preferred Degrees: PharmD, PhD, MS)

Please rank and check any site(s) of interest:

_____ Baylor Scott & White Health/The University of Texas at Austin/Novartis Pharmaceuticals Corporation

_____ Thomas Jefferson University College of Population Health/Novartis Pharmaceuticals Corporation

_____ University of Pittsburgh School of Pharmacy/UPMC Health Plan/Novartis Pharmaceuticals Corporation

Application Process (rolling submission, application deadline is October 17th, 2025 at 11:59 pm EDT):

To apply, please email usheor.fellowship@novartis.com and include the following materials:

- Cover Letter
- Application form with first-year fellowship site(s) preference
- CV
- Email of 2 References

If offered an interview, the following documents will be requested:

- 2 Letters of Recommendation (sent via email from references)
- Unofficial Transcript

Requirements:

Graduate degree in a relevant discipline focused on pharmacy, health services research, health economics, epidemiology, or a related discipline (e.g., PharmD, PhD, MPH, etc.). A background in pharmacy or medicine and experience in outcomes research, health economics, or another related field of research is preferred. Excellent communication skills (oral and written). Demonstrated success in working in teams and independently.

Please email or send the required application materials to:

Monika Salkar, PhD, BPharm
Associate Director, HE&OR and HE&OR Fellowship Director
Email: usheor.fellowship@novartis.com

NOVARTIS | Reimagining Medicine